LINC02431: A Potential Drug Target and Biomarker (G100506122)

Target Name: LINC02431

NCBI ID: G100506122

LINC02431

Other Name(s): Long intergenic non-protein coding RNA 2431 | long intergenic non-protein coding RNA 2431

LINC02431: A Potential Drug Target and Biomarker

LINC02431 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-derived suppressor (MDS) gene, which is responsible for the development of many types of cancer. MDS cells are resistant to chemotherapy and have a higher risk of relapse compared to cancer cells. LINC02431 has been shown to play a crucial role in the regulation of MDS cell growth and survival.

Recent studies have identified LINC02431 as a potential drug target by using various techniques, such as RNA interference and gene expression analysis. These studies have shown that LINC02431 can be targeted by small molecules, making it a promising target for future drug development. In addition, LINC02431 has also been shown to be a potential biomarker for cancer by using various techniques, such as qRT-PCR and western blotting.

One of the main advantages of LINC02431 as a drug target is its specificity. LINC02431 has been shown to be highly specific for its target, MDS cells, and not other cell types. This makes it a promising target for small molecules that can specifically interact with LINC02431 and inhibit its function.

Another advantage of LINC02431 as a drug target is its expression level. LINC02431 is expressed at high levels in many types of cancer, including breast, lung, and ovarian cancer. This makes it an attractive target for small molecules that can increase LINC02431 expression and enhance its function.

In addition to its potential as a drug target, LINC02431 has also been shown to be a potential biomarker for cancer. LINC02431 has been shown to be downregulated in many types of cancer, including breast, lung, and ovarian cancer. This suggests that LINC02431 may be a useful biomarker for cancer diagnosis and monitoring.

Furthermore, LINC02431 has been shown to play a role in the regulation of myeloid-derived suppressor (MDS) cell growth and survival. MDS cells are resistant to chemotherapy and have a higher risk of relapse compared to cancer cells. LINC02431 has been shown to be involved in the regulation of MDS cell growth by interacting with the transcription factor, NF-E2F1.

Overall, LINC02431 is a promising drug target and biomarker for cancer. Its specificity, expression level, and role in the regulation of MDS cell growth make it an attractive target for small molecules that can inhibit its function. Further research is needed to fully understand the potential of LINC02431 as a drug target and biomarker for cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 2431

The "LINC02431 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02431 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets